Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study

MeSH terms

• Adult
• Aged
• Angiogenesis Inhibitors / administration & dosage
• Angiogenesis Inhibitors / adverse effects
• Angiogenesis Inhibitors / pharmacology
• Angiogenesis Inhibitors / therapeutic use
• Antineoplastic Agents / administration & dosage*
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / pharmacology
• Antineoplastic Agents / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / pharmacology
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Arsenic Trioxide
• Arsenicals / administration & dosage*
• Arsenicals / adverse effects
• Arsenicals / pharmacology
• Arsenicals / therapeutic use
• Ascorbic Acid / administration & dosage*
• Ascorbic Acid / adverse effects
• Ascorbic Acid / pharmacology
• Ascorbic Acid / therapeutic use
• Azacitidine / administration & dosage
• Azacitidine / adverse effects
• Azacitidine / analogs & derivatives*
• Azacitidine / pharmacology
• Azacitidine / therapeutic use
• Bone Marrow / blood supply
• Bone Marrow / drug effects
• Bone Marrow Cells / drug effects
• Bone Marrow Cells / metabolism
• Cohort Studies
• Decitabine
• Dose-Response Relationship, Drug
• Female
• Gene Expression Profiling
• Humans
• Leukemia, Myeloid, Acute / drug therapy*
• Leukemia, Myeloid, Acute / metabolism
• Male
• Middle Aged
• Myelodysplastic Syndromes / drug therapy*
• Myelodysplastic Syndromes / metabolism
• Neovascularization, Pathologic / drug therapy
• Oxides / administration & dosage*
• Oxides / adverse effects
• Oxides / pharmacology
• Oxides / therapeutic use
• Young Adult